Latest Kalaris Therapeutics News & Updates

See the latest news and media coverage for Kalaris Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Kalaris Therapeutics

Clinical-stage biopharmaceutical company developing retinal disease treatments

kalaristx.com
Company type
Private company
Number of employees
2–20

Last updated

Latest news about Kalaris Therapeutics

In short: Kalaris Therapeutics reported positive clinical data for its lead asset TH103, completed a merger with AlloVir, and secured $50 million in funding.

Company announcements

Kalaris Therapeutics

Kalaris reports 2025 financial results

Cash stands at $118M, funding operations to Q4 2027. Positive Phase 1a data for TH103 reported; Phase 1b/2 data expected 1H 2027. $50M private placement completed.

Kalaris Therapeutics

Kalaris presents Phase 1 data for TH103

Data on safety, tolerability, pharmacokinetics, and early efficacy in neovascular AMD patients will be presented at the Macula Society Annual Meeting on February 26, 2026.

Unlock all announcements with a

Media coverage

Morningstar

Kalaris Therapeutics Inc KLRS

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive...

MSN

Wedbush initiates coverage of Kalaris Therapeutics (KLRS) with outperform recommendation

Fintel reports that on May 14, 2026, Wedbush initiated coverage of Kalaris Therapeutics (NasdaqGM:KLRS) with a Outperform recommendation. Analyst Price Forecast Suggests 246.82% Upside As...

Unlock all articles with a

Never miss news about Kalaris Therapeutics

Track Kalaris Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Kalaris Therapeutics competitors & trending companies

Browse news for competitors to Kalaris Therapeutics and other trending companies.